These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 39103675)

  • 21. Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations.
    Binder L; Ghadban M; Sit C; Barnard K
    Curr Oncol; 2022 Mar; 29(3):1514-1526. PubMed ID: 35323327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Valve Stenosis at Low Surgical Risk: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(14):1-148. PubMed ID: 33240455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health-state utility estimates for health technology assessment: a review of the manufacturers' submissions to the French National Authority for Health.
    Hamers FF; Ghabri S; Le Gales C
    Expert Rev Pharmacoecon Outcomes Res; 2017 Oct; 17(5):489-494. PubMed ID: 28133977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers' Submissions to the French National Authority for Health.
    Ghabri S; Hamers FF; Josselin JM
    Pharmacoeconomics; 2016 Jun; 34(6):617-24. PubMed ID: 26829942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model.
    Tappenden P; Harnan S; Uttley L; Mildred M; Carroll C; Cantrell A
    Health Technol Assess; 2013 Dec; 17(56):v-xvii, 1-181. PubMed ID: 24290164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The extent and quality of qualitative evidence included in health technology assessments: a review of submissions to NICE and CADTH.
    Szabo SM; Hawkins NS; Germeni E
    Int J Technol Assess Health Care; 2023 Dec; 40(1):e6. PubMed ID: 38126273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost.
    Rawson NS
    Orphanet J Rare Dis; 2017 Mar; 12(1):59. PubMed ID: 28330479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Total hip replacement and surface replacement for the treatment of pain and disability resulting from end-stage arthritis of the hip (review of technology appraisal guidance 2 and 44): systematic review and economic evaluation.
    Clarke A; Pulikottil-Jacob R; Grove A; Freeman K; Mistry H; Tsertsvadze A; Connock M; Court R; Kandala NB; Costa M; Suri G; Metcalfe D; Crowther M; Morrow S; Johnson S; Sutcliffe P
    Health Technol Assess; 2015 Jan; 19(10):1-668, vii-viii. PubMed ID: 25634033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do Health Technology Assessment organisations consider manufacturers' costs in relation to drug price? A study of reimbursement reports.
    Enzing JJ; Knies S; Engel J; IJzerman MJ; Sander B; Vreman R; Boer B; Brouwer WBF
    Cost Eff Resour Alloc; 2022 Aug; 20(1):46. PubMed ID: 36045377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Laparoscopic surgery for inguinal hernia repair: systematic review of effectiveness and economic evaluation.
    McCormack K; Wake B; Perez J; Fraser C; Cook J; McIntosh E; Vale L; Grant A
    Health Technol Assess; 2005 Apr; 9(14):1-203, iii-iv. PubMed ID: 15842951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
    Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
    Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation.
    Colquitt JL; Mendes D; Clegg AJ; Harris P; Cooper K; Picot J; Bryant J
    Health Technol Assess; 2014 Aug; 18(56):1-560. PubMed ID: 25169727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access?
    Rawson NSB
    J Popul Ther Clin Pharmacol; 2020 Feb; 27(1):e48-e64. PubMed ID: 32124580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reimbursement recommendations for cancer drugs supported by phase II evidence in Canada.
    Li YYR; Mai H; Trudeau ME; Mittmann N; Chiasson K; Chan KKW; Cheung MC
    Curr Oncol; 2020 Oct; 27(5):e495-e500. PubMed ID: 33173389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC-Does the Presence of an Explicit Threshold Affect the ICER Proposed?
    Wang S; Gum D; Merlin T
    Value Health; 2018 Aug; 21(8):938-943. PubMed ID: 30098671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conditional Funding Recommendations for Drugs in Canada: A Cross-Sectional Analysis.
    Graili P
    Appl Health Econ Health Policy; 2023 Jul; 21(4):673-681. PubMed ID: 36609982
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.